Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) for her clients.
She is a director of the Texas Life Science Foundation and is actively involved in helping to develop Texas's biotech funding infrastructure as well as being one of several authors of the current Texas Cancer Plan, one of CPRIT's legislative requirements.
This aims to co-ordinate, prioritize and provide an actionable framework to fight the effects of cancer in Texas.
Jason Terrell Volition America’s chief executive, said: "We are delighted to be working with Dr. Vollmer Dahlke to help identify and secure funding to further our development of blood-based cancer diagnostic tests for the US.
“The fact that Texas is one of the leading life science states was a key driver in our decision to make this the home of Volition America, Inc.”
Shares nudged 1.19% higher in New York to stand at $4.25.